Cargando…
Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. We used peripheral blood gene expression and cell-type abundance to identify biomarkers of response and recurrence in neoadjuvant chemotherapy–treated patients with breast...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604512/ https://www.ncbi.nlm.nih.gov/pubmed/36304942 http://dx.doi.org/10.1158/2767-9764.CRC-22-0023 |
_version_ | 1784817832684421120 |
---|---|
author | Axelrod, Margaret L. Wang, Yu Xu, Yaomin Sun, Xiaopeng Bejan, Cosmin A. Gonzalez-Ericsson, Paula I. Nunnery, Sara Bergman, Riley E. Donaldson, Joshua Guerrero-Zotano, Angel L. Massa, Chiara Seliger, Barbara Sanders, Melinda Mayer, Ingrid A. Balko, Justin M. |
author_facet | Axelrod, Margaret L. Wang, Yu Xu, Yaomin Sun, Xiaopeng Bejan, Cosmin A. Gonzalez-Ericsson, Paula I. Nunnery, Sara Bergman, Riley E. Donaldson, Joshua Guerrero-Zotano, Angel L. Massa, Chiara Seliger, Barbara Sanders, Melinda Mayer, Ingrid A. Balko, Justin M. |
author_sort | Axelrod, Margaret L. |
collection | PubMed |
description | Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. We used peripheral blood gene expression and cell-type abundance to identify biomarkers of response and recurrence in neoadjuvant chemotherapy–treated patients with breast cancer. We identified a signature of IFN and complement response that was higher in the blood of patients with pathologic complete response. This signature was preferentially expressed by monocytes in single-cell RNA sequencing. Monocytes are routinely measured clinically, enabling examination of clinically measured monocytes in multiple independent cohorts. We found that peripheral monocytes were higher in patients with good outcomes in four cohorts of patients with breast cancer. Blood gene expression and cell type abundance biomarkers may be useful for prognostication in breast cancer. SIGNIFICANCE: Biomarkers are needed in breast cancer to identify patients at risk for recurrence. Blood is an attractive site for biomarker identification due to the relative ease of longitudinal sampling. Our study suggests that blood-based gene expression and cell-type abundance biomarkers may have clinical utility in breast cancer. |
format | Online Article Text |
id | pubmed-9604512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-96045122022-10-26 Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer Axelrod, Margaret L. Wang, Yu Xu, Yaomin Sun, Xiaopeng Bejan, Cosmin A. Gonzalez-Ericsson, Paula I. Nunnery, Sara Bergman, Riley E. Donaldson, Joshua Guerrero-Zotano, Angel L. Massa, Chiara Seliger, Barbara Sanders, Melinda Mayer, Ingrid A. Balko, Justin M. Cancer Res Commun Research Article Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. We used peripheral blood gene expression and cell-type abundance to identify biomarkers of response and recurrence in neoadjuvant chemotherapy–treated patients with breast cancer. We identified a signature of IFN and complement response that was higher in the blood of patients with pathologic complete response. This signature was preferentially expressed by monocytes in single-cell RNA sequencing. Monocytes are routinely measured clinically, enabling examination of clinically measured monocytes in multiple independent cohorts. We found that peripheral monocytes were higher in patients with good outcomes in four cohorts of patients with breast cancer. Blood gene expression and cell type abundance biomarkers may be useful for prognostication in breast cancer. SIGNIFICANCE: Biomarkers are needed in breast cancer to identify patients at risk for recurrence. Blood is an attractive site for biomarker identification due to the relative ease of longitudinal sampling. Our study suggests that blood-based gene expression and cell-type abundance biomarkers may have clinical utility in breast cancer. American Association for Cancer Research 2022-05-04 /pmc/articles/PMC9604512/ /pubmed/36304942 http://dx.doi.org/10.1158/2767-9764.CRC-22-0023 Text en © 2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. |
spellingShingle | Research Article Axelrod, Margaret L. Wang, Yu Xu, Yaomin Sun, Xiaopeng Bejan, Cosmin A. Gonzalez-Ericsson, Paula I. Nunnery, Sara Bergman, Riley E. Donaldson, Joshua Guerrero-Zotano, Angel L. Massa, Chiara Seliger, Barbara Sanders, Melinda Mayer, Ingrid A. Balko, Justin M. Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer |
title | Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer |
title_full | Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer |
title_fullStr | Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer |
title_full_unstemmed | Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer |
title_short | Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer |
title_sort | peripheral blood monocyte abundance predicts outcomes in patients with breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604512/ https://www.ncbi.nlm.nih.gov/pubmed/36304942 http://dx.doi.org/10.1158/2767-9764.CRC-22-0023 |
work_keys_str_mv | AT axelrodmargaretl peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT wangyu peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT xuyaomin peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT sunxiaopeng peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT bejancosmina peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT gonzalezericssonpaulai peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT nunnerysara peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT bergmanrileye peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT donaldsonjoshua peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT guerrerozotanoangell peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT massachiara peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT seligerbarbara peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT sandersmelinda peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT mayeringrida peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer AT balkojustinm peripheralbloodmonocyteabundancepredictsoutcomesinpatientswithbreastcancer |